Bausch + Lomb Corp's recent FDA meeting signals progress for its treatment of Dry AMD.
Bausch + Lomb Corp has made significant strides in developing a novel oral treatment for Dry Age-related Macular Degeneration (AMD) after a constructive meeting with the FDA. The stock closed at C$24.45, reflecting a 1.72% increase for the day and a 1.81% gain over the past week, though it has seen a decline of 0.84% over the past month. Year-to-date, shares are up 8.69%.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.70B
52W high
$25.70
52W low
$19.36
1W change
+1.81%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO · as of Oct 8, 2026
Wall Street analysts forecast BLCO stock price to rise 4.3% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.83
+4.3% Upside
Previously C$25.79 on Oct 7, 2026
Current Price
C$24.77
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
22.0%
Annualized
90-Day Vol
27.2%
Annualized
Trend (90d)
+31.9%
Annualized drift
90d Mean
C$27.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$25.73 | C$23.84 – C$27.76 |
| 60 trading days | C$26.72 | C$24.00 – C$29.76 |
| 90 trading days | C$27.76 | C$24.33 – C$31.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should monitor Bausch + Lomb's upcoming financial results and the treatment's progress with the FDA.
Bausch + Lomb Shares Up 1.72% Following FDA Meeting News
The stock closed at C$24.45, with a notable increase in trading volume, indicating heightened investor interest.
Bull case
The positive feedback from the FDA could speed up the development and potential approval of the treatment, which would strengthen Bausch + Lomb's position in the market.
Bear case
There are still uncertainties about the treatment's effectiveness and the timeline for FDA approval, which could impact investor sentiment.
What Happened
Advertisement
Bausch + Lomb Corp announced that it is advancing its novel oral treatment for Dry AMD after receiving constructive feedback from the FDA. This development follows a period of focused research and development in the ophthalmology sector. The news comes as the company prepares for its third-quarter financial results, scheduled for release on October 28. The positive interaction with the FDA may accelerate the treatment's timeline, reflecting the company's commitment to addressing significant eye health issues.
What the Numbers Show
Following the announcement, Bausch + Lomb's stock increased by 1.72%, closing at C$24.45. The trading volume reached 200 shares, which is 2.22 times the 20-day average volume of 1,242 shares, indicating heightened interest among investors. The stock is currently trading above the 50-day moving average of C$23.90 by 2.3% and the 200-day moving average of C$23.02 by 6.2%. Over the past year, the stock has experienced a range between C$19.36 and C$25.70, with current pricing positioning it at approximately 80% of this range.
What to Watch Next
Investors should keep an eye on Bausch + Lomb's upcoming third-quarter financial results scheduled for October 28, as well as any further updates regarding the oral treatment's development and FDA approval process. The average analyst target for the stock is C$25.83, suggesting an implied move of 5.6% from the last close. This outlook reflects a moderately bullish stance from analysts, which could influence market sentiment as more information becomes available.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
